Novel oral anticoagulants for heparin-induced thrombocytopenia.
To review the use of the novel oral anticoagulant (NOAC) agents for the treatment of heparin-induced thrombocytopenia (HIT) from relevant clinical trial data. A MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials.gov, and Google-Scholar searches (1966-March 2016) were conducted using the keywords: thrombocytopenia, NOACs, dabigatran, apixaban, rivaroxaban, edoxaban, Xa inhibitor, direct thrombin inhibitor. Articles evaluating the new oral anticoagulants for thrombocytopenia published in English and using human subjects were selected. Eight clinical trials were identified. References cited in identified articles were used for additional citations. Approximately 12 million hospitalized patients each year are exposed to heparin for thromboprophylaxis. HIT, an immune-mediated, prothrombotic adverse reaction is a potential complication of heparin therapy. As a result, heparin products must be immediately withdrawn and replaced by alternative anticoagulants to compensate for the thrombotic risk associated with HIT. Limitations exist with the only currently FDA approved heparin alternative, argatroban. NOACs have been considered as potential alternatives to traditional agents based on their pharmacologic activity. Case reports have indicated positive results in patients, with clinical outcomes and tolerability supporting the use of the NOACs as alternative agents in the treatment of HIT. Positive results have been reported for the use of NOACs in the treatment of HIT. Further robust studies are needed for definitive decision making by clinicians.
Department of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, 800 Lakeshore Drive, Birmingham, AL, 35229, USA. jmwhalen@samford.edu.
Jessica W
JW
Skelley
Department of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, 800 Lakeshore Drive, Birmingham, AL, 35229, USA.
Jeffrey A
JA
Kyle
Department of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, 800 Lakeshore Drive, Birmingham, AL, 35229, USA.
Rachel A
RA
Roberts
D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D010875:Pipecolic Acids / Q000627:therapeutic use; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy*
D000925:Anticoagulants; D010875:Pipecolic Acids; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; C031942:argatroban
Apixaban; Betrixaban; Dabigatran; Direct thrombin inhibitor; Edoxaban; Heparin induced thrombocytopenia; Novel oral anticoagulants; Rivaroxaban; Xa inhibitor